Showing results 1 to 5 of 5
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
AB-729, a GalNAc-siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection Proceeding/Conference:Hepatology International | 2021 | |||
Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects. Poster Presentation (SAT443) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology | 2022 | |||
Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression Proceeding/Conference:Journal of Hepatology | 2021 | 14 | ||
Safety and pharmacodynamics of the GALNAC-siRNA AB-729 in subjects with chronic hepatitis B infection Proceeding/Conference:Hepatology | 2020 | 19 | ||
2019 | 5 |